Robert T. Gerlai is a Canadian behaviour geneticist and behavioural neuroscientist.
Early life and education
Gerlai obtained his PhD in 1987 from the Eötvös Loránd University and the Hungarian Academy of Sciences in Budapest.
Career
Gerlai has worked in the biotechnology (
Genentech) and biopharmaceutical research industries (Eli Lilly and Company and Saegis Pharmaceuticals) as Senior Scientist and Vice President of Research, and led pre-clinical as well as clinical research teams developing drugs to treat mild cognitive impairment and Alzheimer's Disease. He also worked at different universities in North America and Europe. He is a Distinguished Professor of behavioral neuroscience at the Department of Psychology at the University of Toronto.
The Web of Science lists over 350 peer-reviewed publications for Gerlai, which have been cited over 19500 times, resulting in an h-index of 72.
Honours
Gerlai is an elected Fellow of the International Behavioral Neuroscience Society, of which he also has been president.
He is
editor-in-chief of
Behavioral and Brain Functions.
He is editor of the book series
Advances in Experimental Medicine and Biology.
He is a member of the
of
Biology,,
,
,
,
Zebrafish, and
F1000. He is
editing for behavioral neuroscience of
BMC Neuroscience.
In 2013, Gerlai received the Distinguished Scientist Award from the International Behavioural and Neural Genetics Society.
In 2015, he received the Research Excellence Award from the University of Toronto.
In 2019 he received the Outstanding Achievement Award from the International Behavioral Neuroscience Society.
In 2019 and again in 2024, he received the 5-year John Carlin Roder Distinguished Professorship in Behavioural Neuroscience at the University of Toronto Mississauga.
In 2023, he was elected Fellow of the Royal Society of Canada, Academy of Science.
In 2024, he received the IQ Consortium/AAALAC International Global 3Rs Award for his significant and innovative contributions to ethical and humane use of animals in research.
External links
